FluoGuide’s update on FG001’s clinical development
Copenhagen, Denmark, 24 August 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) provides an update on the clinical development of FG001.FluoGuide announced in April FG001’s highly promising results in aggressive brain cancer (high grade glioma) following its phase I/IIa trial. FG001 was demonstrated to be well tolerated with only few patients reporting mild side effects (3 out of 40 patients). Furthermore, 100% of the biopsies from patients in the optimal dose (n=8, with 33 biopsies obtained) had their cancer illuminated. Based on these strong results, FluoGuide has decided to expand the